Ligands of peroxisome proliferator-activated receptor-gamma increase the generation of vascular endothelial growth factor in vascular smooth muscle cells and in macrophages

• Autorzy: Jozkowicz A. , Dulak J. , Piatkowska E. , Placha W. , Dembinska-Kiec A.
• Języki publikacji: EN

Abstrakty

EN

Peroxisome proliferator-activated receptors-gamma (PPARgamma) are ligand-inducible transcription factors of the nuclear hormone receptor superfamily. We examined the effect of PPARgamma activation on the generation of vascular endothelial growth factor (VEGF), one of the major angiogenic agents. Rat vascular smooth muscle cells (VSMC) and murine macrophages RAW264.7 were incubated for 24 h with PPARgamma activators: prostaglandin J2 and ciglitazone. PPARgamma were expressed in VSMC and RAW cells and their activity was upregulated in the presence of PGJ2 and ciglitazone. Incubation of the cells with PPARgamma activators significantly augmented the release of VEGF protein into the media, both in resting and in IL-1beta- or LPS-stimulated cultures. The higher protein generation was connected with the increased expression of mRNA and transcriptional activation of VEGF promoter. We conclude that the activation of PPARgamma upregulates the generation of VEGF and may be involved in the regulation of angiogenesis.

Słowa kluczowe

EN

ciglitazone; ligand; prostaglandin J2; macrophage; vascular smooth muscle; thiazolidinedione; peroxisome proliferator-activated receptor gamma; angiogenesis; muscle cell; vascular endothelial growth factor

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2000
• Tom: 47
• Numer: 4
• Opis fizyczny: p.1147-1157,fig.,ref.

Twórcy

autor

Jozkowicz A.

• University of Vienna, Waehringer Guertel 18-20, Vienna, A-1090 Austria

autor

Dulak J.

autor

Piatkowska E.

autor

Placha W.

autor

Dembinska-Kiec A.

Bibliografia

• 1. Michalik, L. & Wahli, W. (1999) Peroxisome proliferator-activated receptors: Three iso­types for a multitude of functions. Curr. Opin. Biotechnol. 10, 564-570.
• 2. Motojima, K., Passilly, P., Peters, J.M. & Gon­zales, F.J. (1998) Expression of putative fatty acid transporter genes are regulated by pero- xisome proliferator-activated receptor alpha and gamma activators in a tissue- and in- ducer-specific manner. J. Biol. Chem. 273, 16710-16714.
• 3. Tontonoz, P., Hu, E., Devine, J., Beale, E.G. & Spiegelman, B.M. (1995) PPARy2 regulates adipose expression of phosphoenolopyruvate carboxykinase gene. Mol. Cell Biol. 15, 351­357.
• 4. Schoonjans, K., Watanabe, M., Suzuki, H., Mahfoudi, A., Krey, G., Wahli, W., Grimaldi, P., Staels, B., Yamamoto, T. & Auwerx, J. (1995) Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator re­sponse element in the C promoter. J. Biol. Chem. 270, 19269-19276.
• 5. Rodriquez, J.C., Gil-Gomez, G., Hegardt, F.G. & Haro, D. (1994) Peroxisome proliferator-ac- tivated receptor mediates induction of the mi- tochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids. J. Biol. Chem. 269, 18767-18772.
• 6. Ribon, V., Johnson, J.H., Camp, H.S. & Saltiel, A.R. (1998) Thiazolidinediones and in­sulin resistance: Peroxisome proliferator-acti- vated receptor gamma activation stimulates the expression of CAP gene. Proc. Natl. Acad. Sci. U.S.A. 95, 14751-14756.
• 7. Elstner, E., Muller, C., Koshizuka, K., Wiliam- son, E.A., Park, D., Asou, H., Shintaku, P., Said, J.W., Heber, D. & Koeffler, H.P. (1998) Ligands for peroxisome proliferator- activated receptor gamma and retinoic acid receptor in­hibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. U.S.A. 95, 8806-8811.
• 8. Kubota, T., Koshizuka, K., Williamson, E.A., Asou, H., Said, J.W., Holden, S., Miyoshi, I. & Foeffler, H.P. (1998) Ligand for peroxisome proliferator-activated receptor gamma (tro- glitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 58, 3344-3352.
• 9. Sarraf, P., Mueller, E., Jones, D., King, F.J., De Angelo, D.J., Partridge, J.B., Holden, S.A., Chen, L.B., Singer, S., Fletcher, C. & Spiegelman, B.M. (1998) Differentiation and reversal of malignant changes in colon cancer through PPARy. Nature Med. 4, 1046-1052.
• 10. Yoshimoto, T., Naruse, M., Shizume, H., Naruse, K., Tanabe, A., Tanaka, M., Tago, K., Irie, K., Muraki, T., Demura, H. & Zardi, L. (1999) Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hyper­trophy. Atherosclerosis 145, 333-340.
• 11. Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nature Med. 1, 27-31.
• 12. Schaper, W. & Buschmann, I. (1999) VEGF and therapeutic opportunities in cardiovascu­lar diseases. Curr. Opin. Biotechnol. 10, 541­543.
• 13. Adamis, A.P., Miller, J.W., Bernal, M.T., D'Amico, D.J., Yeo, T.K. & Yeo, K.T. (1994) In­creased vascular endothelial growth factor lev­els in the vitreous of eyes with proliferative retinopathy. Am. J. Ophthalmol. 118, 445­450.
• 14. Aiello, L.P., Avery, R.L., Arring, P.G., Keyt, B.A., Jampel, H.D., Shah, S.T., Pasquale, L.R., Thieme, H., Iwamoto, M.A., Park, J.E., Nguyen, M.S., Aiello, L.M., Ferrara, N. & King, G.L. (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other disorders. N. Engl. J. Med. 331, 1480-1487.
• 15. Malecaze, F., Favard, C., Simorre-Pinatel, V., Mathis, A., Chollet, P., Favard, C., Bayard, F. & Plouet, J. (1994) Detection of vascular endo­thelial growth factor messenger RNA and vas­cular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch. Op­hthal. 112, 1476-1482.
• 16. Pe'er, J., Shweiki, D., Itin, A., Hemo, I., Gnessin, H. & Keshet, E. (1995) Hypoxia-in- duced expression of vascular endothelial growth factor by retinal cells is a common fac­tor in neovascularizing ocular diseases. Lab. Invest. 72, 638-645.
• 17. Aiello, L.P., Pierce, E.A., Foley, E.D., Takagi, H., Chen, H., Riddle, L., Ferrara, N., King, G. L. & Smith, L.E.H. (1995) Suppression of retinal neovascularization in vivo by inhibi­tion of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. U.S.A. 92, 10457-10461.
• 18. Robinson, G.S., Pierce, E.A., Rook, S.L., Foley, E., Webb, R. & Smith, L.E.S. (1996) Oligodeoxynucleotides inhibit retinal neovas­cularization in a murine model of proliferative retinopathy. Proc. Natl. Acad. Sci. U.S.A. 93, 4851-4856.
• 19. Adamis, A.P., Shima, D.T., Tolentino, M.J., Gragoudas, E.S., Ferrara, N., Folkman, J., D'Amore, P.A. & Miller, J.W. (1996) Inhibi­tion of vascular endothelial growth factor pre­vents retinal ischemia-associated iris neovas- cularization. Arch. Ophthalmol. 114, 66-71.
• 20. Okamoto, N., Tobe, T., Hackett, S.F., Ozaki, H. , Vinores, M., LaRochelle, W., Zack, D.J. & Campochiaro, P.A. (1997) Transgenic mice with increased expression of vascular endothe­lial growth factor in the retina. A new model of intraretinal and subretinal neovascula- rization. Am. J. Pathol. 151, 281-291.
• 21. Xin, X., Suya, Y., Kowalski, J. & Gerristen, M.E. (1999) Peroxisome proliferator-activated receptor-y ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem. 274, 916-921.
• 22. Bishop-Bailey, D. & Hla, T. (1999) Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-delta12, 14-prostaglandin J2. J. Biol. Chem. 274, 17042-17048.
• 23. Chomczynski, P. & Sacchi, N. (1987) Single step method of RNA isolation by acid guani- dinum thiocyanate-phenol-chlorophorm ex­traction. Anal. Biochem. 162, 156-159.
• 24. Yu, K., Bayona, W., Kallens, C.B., Harding, H.P., Ravera, C.P., McMahon, G., Brown, M., & Lazar, M.A. (1995) Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J. Biol. Chem. 270, 23975­23983.
• 25. Yamakawa, K., Hosoi, M., Koyama, H., Ta- naka, S., Fukumoto, S., Morii, H., & Nishi- zawa, Y. (2000) Peroxisome proliferator-acti- vated receptor-gamma agonists increase vas­cular endothelial growth factor expression in human vascular smooth muscle cell. Biochem. Biophys. Res. Commun. 271, 571- 574.
• 26. Bamba, H., Ota, S., Kato, A., Kawamoto, C., Fujiwara, K. (2000) Prostaglandins up-re- gulate vascular endothelial growth factor pro­duction through distinct pathways in differen­tiated U937 cells. Biochem. Biophys. Res. Commun. 273, 485-491.
• 27. Tontonoz, P., Nagy, L., Alvarez, J.G., Tho- mazy, V.A., Evans, R.M. (1998) PPARy pro­motes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93, 241-252.
• 28. Ricote, M., Huang, J., Fajas, L., Li, A., Welch, J., Najib, J., Witzum, J.L., Auwerx, J., Palin- ski, W. & Glass, C.K. (1998) Expression of the peroxisome proliferator-activated receptor gamma (PPARy) in human atherosclerosis and regulation in macrophages by colony stim­ulating factors and oxidized LDL. Proc. Natl. Acad. Sci. U.S.A. 95, 7614-7619.
• 29. Steals, B., Koenig, W., Habib, A., Merval, R., Lebret, M., Torra, I.P., Delerive, P., Fadel, A., Chinetti, G., Fruchard, J.C., Najib, J., Maclouf, J. & Tedgui, A. (1998) Activation of human aortic smooth muscle cells is inhibited by PPARa but not by PPARy activators. Na­ture 393, 790-793.
• 30. Iijima, K., Yoshizumi, M., Ako, J., Eto, M., Kim, S., Hashimoto, M., Sugimoto, N., Liang, Y.Q., Sudoh, N., Toba, K. & Ouchi, Y. (1998) Expression of peroxisome proliferator-acti­vated receptor-y (PPARy) in rat aortic smooth muscle cells. Biochem. Biophys. Res. Commun. 247, 353-356.
• 31. Pasceri, V., Wu, H.D., Willerson, J.T. & Yeh, E.T.H. (2000) Modulation of vascular inflam­mation in vitro and in vivo by peroxisome proliferator-activated receptor-y activator. Cir­culation 101, 235-240.
• 32. Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J. & Glass, C.K. (1998) The peroxisome prolife- rator-activated receptor gamma is a negative regulator of macrophage activation. Nature 391, 79-82.
• 33. Jiang, C., Ting, A.T. & Seed, B. (1998) PPARy agonists inhibit production of monocyte in­flammatory cytokines. Nature 391, 82-86.
• 34. Momoi, A., Murao, K., Imachi, H., Yoshitaka, S., Nakamura, H., Hosokawa, H., Sato, M., Fujita, J., Okada, H., Ishida, T. & Takahara, J. (1999) Thiazolidinedione inhibits production of RANTES in cytokine-treated human lung epithelial cell line. FEBSLett. 452, 301-304.
• 35. Murao, K., Imachi, H., Atsuko, M., Sayo, Y., Hosokawa, H., Sato, M., Ishida, T. & Takahara, J. (1999) Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells. FEBSLett. 454, 27-30.
• 36. Law, R.E., Meehan, W.P., Xi, X.P., Graf, K., Wuthrich, D.A., Coats, W., Faxon, D. & Hsueh, W.A. (1996) Troglitazone inhibits vas­cular smooth muscle cell growth and intimal hyperplasia. J. Clin. Invest. 98, 1897-1905.
• 37. Kihara, S., Ouchi, N., Funahashi, T., Shino- hara, E., Tamura, R., Yamashita, S. & Matsu- zawa, Y. (1998) Troglitazone enhances glucose uptake and inhibits mitogen-activated protein kinase in human aortic smooth muscle cells. Atherosclerosis 136, 163-168.
• 38. Papapetropoulos, A., Garcia-Cardena, G., Madri, J.A. & Sessa, W.C. (1997) Nitric oxide production contributes to the angiogenic prop­erties of vascular endothelial growth factor in human endothelial cells. J. Clin. Invest. 100, 3131-3139.
• 39. Parenti, A., Mordibelli, L., Cui, X.L., Douglas, J.G., Hood, J.D., Granger, H.J., Ledda, F. & Ziche, M. (1998) Nitric oxide is a upstream sig­nal of vascular endothelial growth factor-in­duced extracellular signal-regulated kinase-1/ 2 activation in postcapillary endothelium. J. Biol. Chem. 273, 4220-4226.
• 40. Satoh, H., Tsukamoto, K., Hashimoto, Y., Hashimoto, N., Togo, M., Hara, M., Maekawa, H., Isoo, N., Kimura, S. & Watanabe, T. (1999) Thiazolidinediones suppress endothelin-1 se­cretion from bovine endothelial cells: A new possible role of PPARy on vascular endothelial function. Biochem. Biophys. Res. Commun. 254, 757-763.
• 41. Delerive, P., Martin-Nizard, F., Chinetti, G., Trottein, F., Fruchard, J.C., Najib, J., Duriez, P. & Steals, B. (1999) Peroxisome proliferator- activated receptor activators inhibit thrombin- induced endothelin-1 production in human vascular endothelial cells by inhibiting the ac­tivator protein-1 signaling pathway. Circ. Res. 85, 394-402.
• 42. Aiello, L.P. (1997) Vascular endothelial growth factor and the eye: Biochemical mecha­nisms of action and implications for novel therapies. Ophthalmic Res. 29, 345-362.
• 43. Hammes, H.P., Lin, J., Bretzel, R.G., Brownle, M. & Breier, G. (1998) Upregulation of the vas- cular endothelial growth factor/vascular endo­thelial growth factor receptor system in exper­imental background diabetic retinopathy of the rat. Diabetes 47, 401-406.
• 44. Kimura, H., Weisz, A., Karashima, Y., Hashi­moto, K., Ogura, T., D'Acqusto, F., Addeo, R., Makuchi, M. & Esumi, H. (2000) Hypoxia reponse element of the human vascular endo- thelial growth factor gene mediates trans- criptional regulation by nitric oxide: Control of hypoxia — inducible factor-1 activity by ni­tric oxide. Blood 95, 189-197.
• 45. Finkenzeller, G., Sparacio, A., Technau, A., Marme, D. & Siemeister, G. (1997) SP1 recog­nition sites in the proximal promoter of the hu­man vascular endothelial growth factor gene are essential for platelet derived growth fac­tor-induced gene expression. Oncogene 15, 669-676.
• 46. Ryuto, M., Ono, M., Izumi, H., Yoshida, S., Weich, H.A., Kohna, K. & Kuwano, M. (1996) Induction of vascular endothelial growth fac­tor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J. Biol. Chem. 271, 28220-28228.
• 47. Krey, G., Mahfoudi, A. & Wahli, W. (1995) Functional interactions of peroxisome proli- ferator-activated receptor, retinoid X-recep- tor, and SP1 in the transcriptional regulation of the acyl-coenzyme A oxidase promoter. Mol. Endocrinol. 9, 19-31.
• 48. Missbach, M., Jagher, B., Siga, I., Nayeri, S., Carlberg, C. & Wiesenberg, I. (1996) Thiazo- lidine diones specific ligands of the nuclear re­ceptor retinoid Z receptor/retinoid acid recep­tor-related orphan receptor alpha with potent antiarthritic activity. J. Biol. Chem. 271, 13515-13522.
• 49. Winrow, C.J., Capone, J.P. & Rachubinski, R.A. (1998) Cross-talk between orphan nu­clear hormone receptor RZRa and peroxisome activated-receptor alpha in regulation of the peroxisome hydratase-dehydrogenase gene. J. Biol. Chem. 273, 31442-31448.
• 50. Kitamura, Y., Kakimura, J., Matsuoka, Y., Nomura, Y., Gebicke-Haerter, P.J. & Tani- guchi, T. (1999) Activators of peroxisome proliferator-activated receptor-y (PPARy) in­hibit inducible nitric oxide synthase expres­sion but increase heme oxygenase-1 expres­sion in rat glial cells. Neurosci. Lett. 262, 129-132.
• 51. Jozkowicz, A., Placha, W., Krzesz, R., Dulak, J. & Dembinska-Kiec, A. (2000) Effect of linoleic acid on the expression of nitric oxide synthase and heme oxygenase-1 in rat vascu­lar smooth muscle cells;in Advances in Lipo- protein and Atherosclerosis Research. Proc. 10th International Dresden Symposium on Lipo- protein and Atherosclerosis, in press.
• 52. Dulak, J., Jozkowicz, A., Foresti, R., Green, C. & Motterlini, R. (1999) Regulation of VEGF synthesis in vascular smooth muscle cells by carbon monoxide and nitric oxide metabolic pathways. Angiogenesis and Tumors, pp. 22-25, October 1999, Paris, France. Abstract.